跳至主要内容
临床试验/NCT05961865
NCT05961865招募中不适用

Change in Inflammatory State in Patients Undergoing Transcatheter Ablation of Atrial Fibrillation

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2023年7月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
180
试验地点
1
主要终点
Prevalence of subjects with AF undergoing ablation who have a reduction of inflammatory burden following treatment.

研究概览

简要总结

It is a non-pharmacological (biological), spontaneous observational study. The main objective is to evaluate the correlation between inflammation markers and local adiposity, clinical risk factors and their possible variation following an AF ablation procedure

详细描述

The study includes the execution of a sample for each time point for the evaluation of inflammation and fibrosis markers identified so far in the literature, such as Interleukin 6, N-terminal propeptide of procollagen type 1 (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Paroxysmal or persistent AF;
  • Patients undergoing ESC/ERAH(European Society of Cardiology/European Heart Rhythm Association) approved catheter ablation procedures;
  • Aged between 18 and 85 years;
  • Ability to provide informed consent for study participation.

排除标准

  • Age > 85 years or < 18 years;
  • Presence of left auricular thrombosis on pre-procedural transesophageal echocardiogram;
  • NYHA functional class IV;
  • Left ventricular ejection fraction <30%;
  • Myocardial infarction or unstable angina or recent coronary artery bypass graft (<6 months);
  • Significant co-morbidity, such as cancer, severe renal failure requiring dialysis, severe obstructive pulmonary disease, cirrhosis, with a life expectancy of less than 12 months;
  • Presence of contraindications to the procedure;
  • Inability to provide informed consent for study participation.

结局指标

主要结局

Prevalence of subjects with AF undergoing ablation who have a reduction of inflammatory burden following treatment.

时间窗: One year

Outcome measured through biochemical analyzes conducted on the patient: interleukin 6 (pg/ml), procollagen type 1 N-terminal propeptide (µg/l), chitinase-3-like protein 1(ng/ml), tumor necrosis factor -TNF-alpha - (pg/ml), GlycA (mmol/mol).

次要结局

  • Prevalence of subjects with AF undergoing ablation who show improvement in clinical terms and in the arrhythmia recurrence rate.(One year)
  • Relationship between the degree of inflammation and atrial fibrosis and the degree of atrial fibrosis detected by electroanatomical mapping.(One year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Stefano Carugo

Director of the Department of Cardio-Thoracic-Vascular Diseases

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

研究点 (1)

Loading locations...

相似试验